Pravastatin: A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease

PharmacoEconomics

Volumn 14, Issue 2, 1998, Pages 217-236

  Coukell, Allan J ^a   Wilde, Michelle I ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; MYOPATHY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; LIPIDS; PRAVASTATIN;

EID: 0031850409     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814020-00010     Document Type: Review

References (75)

1. Reckless JPD. The economics of cholesterol lowering Baillieres Clin Endocrinol Metab 1990; 4 (4): 947-72
2. Reckless JPD. Cost implications of lipid-lowering treatments. Pharmacoeconomics 1994; 6 (4): 310-23
3. Reckless JPD. Cost-effectiveness of hypolipidaemic drugs. Postgrad Med J 1993; 69 Suppl. 1: S30-3
4. Kuntz KM, Lee TH. Cost-effectiveness of accepted measures for intervention in coronary heart disease. Coron Artery Dis 1995; 6: 472-8
5. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994 Mar; 89: 1333-445
6. Thelle DS. Epidemiology of hypercholesterolemia and European management guidelines. Cardiology 1990; 77 Suppl. 4: 2-7
7. Schucker B, Wittes JT, Santanello NC, et al. Change in cholesterol awareness and action: results from national physician and public surveys. Arch Intern Med 1991; 151: 666-73
8. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-52
9. Goa KL, Barradell LB, McTavish D. Simvastatin: a reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. Pharmacoeconomics 1997 Jan; 11: 89-110
10. Hay J, Yuan Y, LaPuerta P, et al. The lifetime medical costs of cardiovascular disease in the United Stales [abstract no. LC-23]. Association for Pharmacoeconomics and Outcomes Research: The APOR Lipid Conference: 1997 Nov 5.6.7: Orlando, FL
11. Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997 Feb; 53: 299-336
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
13. Center for Cardiovascular Education, Inc. AFCAPS/TexCAPS trial demonstrates that first acute major coronary events were reduced by 36% with lovastatin treatment in persons with average to mildly elevated cholesterol levels and low HDL levels. In: Heart Information Network [online]. Center for Cardiovascular Education, Inc., 1998. Available from: URL: http://www.heartinfo.org/news/afcaps112097.htm [Accessed 1998 Jun 19]
14. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 Nov 16; 333: 1301-7
15. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335 (14): 1001-9
16. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-7
17. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 74: 38-42
18. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia hy atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-82
19. Illingworth CR, Torbert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors [review]. Clin Ther 1994; 16: 366-85
20. Oliver MF, Pyörälä K, Shepherd J. Management of hyperlipidaemia: why, when and how to treat. Eur Heart J 1997 Mar; 18: 371-5
21. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5
22. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDLconcentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446-52
23. Tonkin A, LIPID Study Group. The long term intervention with pravastatin in ischaemic disease (LIPID) study results [abstract no. S63]. Atherosclerosis 1998; 136 Suppl.: S39
24. Glasziou PP, Simes J, Hall J, et al. Design of a cost-effectiveness study within a randomized trial: the LIPID trial for secondary prevention of IHD. Controlled Clin Trials 1997; 18: 464-76
25. Pitt B, Ellis SG, Mancini J, et al. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 1993; 72: 31-5
26. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Controlled Clin Trials 1992; 13: 495-506
27. Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995 Oct 1; 92: 1758-64
28. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40
29. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995 Nov 1; 92: 2419-25
30. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996 Aug 15; 78: 409-14
31. Furberg CD, Pitt B, Byington RP, et al. Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995; 76: 60C-3C
32. Newman TJ, Kassler-Taub KB, Gelarden RT, et al. Safety of pravastatin in long-term clinical trials conducted in the United States. J Drug Dev 1990; 3 Suppl. 1: 275-81
33. Johannesson M, Borgquist L, Jonsson B, et al. The cost effectiveness of lipid lowering in Swedish primary health care. J Intern Med 1996 Jul; 240: 23-9
34. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997 Dec 13; 315: 1577-82
35. Drummond MF, Heyse J, Cook J, et al. Selection of end points in economic evaluations of coronary-heart-disease interventions. Med Decis Making 1993; 13: 184-90
36. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994; 16 (6): 1052-62
37. Lindholm LH, Ekbom T, Dash C, et al. Changes in cardiovascular risk factors by combined pharmacological and non-pharmacological strategies: the main results of the CELL study. J Intern Med 1996; 240: 13-22
38. Perreault S, Hamilton VH, Lavoie F, et al. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1996; 10: 787-94
39. Pharoah P. Economic benefit analysis of primary prevention with pravastatin [letter]. BMJ 1998; 316: 1241
40. Freemantle N, Mason J. Economic benefit analysis of primary prevention with pravastatin [letter]. BMJ 1998; 316: 1241
41. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256 (20): 2835-8
42. Pharmacoeconomic modeling disclaimer proposed by ISPOR panel. FDC Reports Pink Sheet 1998 Mar 2: 8
43. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1-11
44. Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ 1997; 6: 589-601
45. Gazzaniga P, Garattini L. Economic evaluation of pharmaceuticals. A critical appraisal of seven studies on cholesterol-lowering agents. Pharmacoeconomics 1992 Oct; 2: 270-8
46. Caro JJ, Avorn J, Jackson JD, et al. Discounting health benefits in pharmacoeconomic analyses: is it justified? [abstract no. 246]. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 2: S117
47. Katz DA, Welch G. Discounting in cost-effectiveness analysis of healthcare programmes. Pharmacoeconomics 1993; 3 (4): 276-85
48. Hillman AL, Kim MS. Economic decision making in healthcare: a standard approach to discounting health outcomes. Pharmacoeconomics 1995; 7(3): 198-205
49. Caro JJ, Payne K, Klittich W, et al. Preventing cardiovascular disease: is primary prevention with pravastatin worth the money? [abstract no. CVB5]. Value in Health 1998; 1 (1): 34
50. Huse DM, Russell MW, Kraemer DF, et al. Cost-effectiveness of HMG-CoA reductase inhibition in primary prevention of CHD: new evidence comparing all available agents [abstract no. LC-21]. Association for Pharmacoeconomics and Outcomes Research: The APOR Lipid Conference. 1997 Nov 5.6.7: Orlando, FL
51. Hilleman DE, Mohiuddin SM, Wurdeman RL, et al. The CURVES trial: a pharmacoeconomic evaluation [abstract no. LC-19]. Association for Pharmacoeconomics and Outcomes Research: The APOR Lipid Conference. 1997 Nov 5.6.7: Orlando, FL
52. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of CHD: comparison between the US and Belgium of a projected risk model [abstract]. European Atherosclerosis Society: 66th Congress: 1996 Jul 13-17: Milan, Italy
53. Elliot WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of myocardial infarction [abstract no. LC-15]. Association for Pharmacoeconomics and Outcomes Research: The APOR Lipid Conference. 1997 Nov 5.6.7: Orlando, FL
54. Caro JJ, Klittich WS, WOSCOPS Economic Analysis Commutee. Implication of preventing disease on life years gained (LYG) [abstract no. PMD 16]. Value in Health 1998; 1 (1): 77
55. Caro JJ. Economic benefit analysis of primary prevention with pravastatin [reply]. BMJ 1998; 316: 1241
56. Mason J. The generalisability of pharmacoeconomic studies. Pharmacoeconomics 1997; 11: 503-14
57. Caro JJ, Klittich WS. Is an ounce of prevention worth a pound of cure? [abstract no. 145]. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 2: S68
58. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995 Apr 27; 332: 1125-31
59. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458-62
60. Neil HAW, Roe L, Godlee RJP, et al. Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins and antioxidants. BMJ 1996; 310: 569-73
61. Caggiula AW, Watron JE, Kuller LH, et al. Cholesterol-Lowering Intervention Program: effect of the Step I Diet in community office practices. Arch Intern Med 1996 Jun 10; 156: 1205-13
62. Roderick P, Ruddock V, Hunt P, et al. A randomized trial to evaluate the effectiveness of dietary advice by practice nurses in lowering diet-related coronary heart disease risk. Br J Gen Pract 1997; 47: 7-12
63. Family Heart Study Group. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. BMJ 1994; 308: 313-20
64. Imperial Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK study. BMJ 1995; 310: 1099-104
65. Plans Rubió P. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain. Public Health 1997; 111: 33-40
66. Denke MA. Cholesterol-lowering diets: a review of the evidence. Arch Intern Med 1995; 155: 17-26
67. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996 Jul; 17: 1001-7
68. Johannesson M, Jönsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997 Jan 30; 336: 332-6
69. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 33-40
70. Goldman L, Garber AM, Grover SA, et al. Task force 6. Cost effectiveness of asessment and management of risk factors. J Am Coll Cardiol 1996; 27 (5): 964-1047
71. Maynard A. Developing the health care market. Economic Journal 1991; 101: 1277-86
72. Hay JW, Wittels EH, Gotto Jr AM. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction [see comments]. Am J Cardiol 1991 Apr 15; 67: 789-96
73. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991 Mar 6; 265: 1145-51
74. Tosteson ANA, Rosenthal DI, Melton III J, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594-603
75. Littenberg B, Garber AM, Sox Jr HC. Screening for hypertension. Ann Intern Med 1990; 112 (3): 192-202